Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
Universität Hamburg · University Medical Center Hamburg-Eppendorf · +5 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
781
total citations
- FWCI
- 39.46
- Percentile
- 100%
- References
- 31
Citations per year
Authors
9- CBCarsten BokemeyerCorresponding
Universität Hamburg, University Medical Center Hamburg-Eppendorf
- IBIgor Bondarenko
Dnipro State Medical University
- JHJ.T. Hartmann
University Children's Hospital Tübingen
- FDFilippo de Braud
European Institute of Oncology
- GSGunter Schuch
Universität Hamburg, University Medical Center Hamburg-Eppendorf
Topics & keywords
Topics
Keywords
- KRAS
- Cetuximab
- Medicine
- FOLFOX
- Colorectal cancer
- Oncology
- Internal medicine
- Oxaliplatin
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.